EXPO vs HURN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: HURN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EXPO and HURN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EXPO and HURN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Exponent, Inc. is a Menlo Park, California engineering and scientific consulting firm founded in 1967 that solves complex technical problems for corporations, law firms, insurers, and government agencies. Its two segments are Engineering and Other Scientific (roughly 85% of net revenues), covering failure analysis, product testing, user research, and disputes across consumer electronics, energy, utilities, transportation, and life sciences, and Environmental and Health (about 15%). The business is people-based rather than asset-based, so its economics revolve around billable hours, staff utilization, and realized billing rates, and its brand as a science-for-hire authority lets it command premium fees on reactive, high-stakes engagements.

Full EXPO guide

Huron Consulting Group was formed in 2002 by former Arthur Andersen partners and has built itself into a global professional services firm organized around three industry segments. Healthcare produced ~50% of revenues before reimbursable expenses in the first half of 2026, Education ~29%, and Commercial ~21%. The work runs through two capabilities: consulting and managed services covers performance improvement, cost reduction, clinical operations, revenue cycle and research administration, while the digital practice implements and then operates enterprise platforms from Workday, Oracle and Salesforce for the same client base. As of June 30, 2026 Huron employed ~5,335 revenue-generating professionals outside managed services, plus ~3,913 managed services staff, a headcount that more than doubled year over year after the RelateCare acquisition added roughly ~1,100 people in patient access. Buying capability is a standing part of the model, with Eclipse Insights, Treliant and WP&C folded in during 2025.

Full HURN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• EXPO drivers: Reactive and disputes demand; AI-enabled products and new risk categories.
• HURN drivers: Healthcare demand and the shift toward managed services; Education, where budget stress is itself the demand driver.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. For HURN, the central risk is the one the market has already repriced twice this year: if generative AI compresses the hours clients will pay for, a business built on utilization and staffing leverage degrades fast, and Huron's consulting utilization near ~81% sits closer to the top of its historical range than the bottom.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EXPO if you believe its drivers more; HURN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EXPO and HURN guides.

EXPO. Exponent's Q1 2026 revenue rose about 14% to roughly $166 million with net income up 11% to about $30 million, aided by 76% utilization and roughly 399,000 billable hours. The shares typically trade at a rich valuation, with a trailing P/E in the low-to-mid 30s, reflecting the market's view of the franchise as a durable, high-quality compounder. The company continues to return cash aggressively, paying dividends and repurchasing stock while expanding its buyback authorization.

HURN. At roughly ~$152 a share against ~15.9M shares outstanding, Huron carries a market capitalization near ~$2.4B and an enterprise value around ~$3.2B once net debt is counted. That works out to about ~16x the midpoint of management's 2026 adjusted EPS guidance and roughly ~12x guided adjusted EBITDA, below where the larger listed consultancies have typically traded. Trailing GAAP earnings look considerably weaker than the adjusted figures because of intangible amortization, transaction costs and investment write-downs, and the gap between the two is wide enough to be worth re-checking each quarter.

Headline figures (approximate, JULY 2026): EXPO shows revenue (ttm, gross) ~$580M, q1 2026 revenue ~$166M (+14% YoY), q1 2026 eps (diluted) ~$0.59, ebitda margin (net rev.) ~28%; HURN shows revenue (ttm, before reimbursable expenses) ~$1.77B, 2026 rbr guidance ~$1.85B to ~$1.89B, adjusted diluted eps guidance (2026) ~$9.00 to ~$9.40, market cap ~$2.4B.

EXPO and HURN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EXPO and HURN exposure against your real portfolio. It is not an investment adviser.